Clinicopathologic features of the cohort
| Characteristic . | Total cohort (N = 188) . | CCUS (n = 6) . | MDS and MDS/AML (n = 80) . | AML (n = 102) . | |
|---|---|---|---|---|---|
| 0% to <10% blasts (n = 61) . | 10% to <20% blasts (n = 19) . | ≥20% blasts . | |||
| Age at dx (y), median (range) | 68.5 (28.0-88.0) | 69.5 (56.5-79.1) | 68.5 (38.0-84.0) | 71.1 (38.5-81.0) | 68.3 (28.0-88.0) |
| Sex, male, n (%) | 98 (52) | 3 (50) | 27 (44) | 13 (68) | 55 (54) |
| CBC at dx, median (range) | |||||
| ANC, ×103/μL | 0.8 (0-16.1) | 2.7 (0.5-4.6) | 1.4 (0.1-11.5) | 1.2 (0.3-2.5) | 0.6 (0.0-16.1) |
| Hb, g/dL | 8.4 (5.5-14.1) | 10.6 (7.3-13.2) | 8.8 (5.6-13.8) | 8.4 (6.6-12.3) | 8.3 (5.5-14.1) |
| Plt, ×103/μL | 48 (7-347) | 123 (81-232) | 62 (7-347) | 51 (8-114) | 36 (7-228) |
| BM blast %, median (range) | 23 (0-100) | 2 (0.5-2.5) | 3 (0-9.5) | 15 (10-17.5) | 35 (20.8-100) |
| Karyotype | |||||
| Complex, n (%) | 161 (86) | 0 (0) | 47 (77) | 19 (100) | 95 (93) |
| Monosomal, n (%) | 154 (82) | 0 (0) | 46 (75) | 17 (90) | 91 (89) |
| Del 17/17p, n (%) | 56 (30) | 0 (0) | 12 (20) | 4 (21) | 40 (40) |
| Mutations by NGS | |||||
| 1 TP53 mutation, n (%) | 145 (77) | 6 (100) | 43 (70) | 15 (79) | 80 (78) |
| ≥2 TP53 mutations, n (%) | 43 (23) | 0 (0) | 18 (30) | 4 (21) | 21 (21) |
| Highest TP53 VAF, median (range) | 41 (1.1-97) | 8.9 (4.5-14.0) | 35 (4-97) | 41 (4-89) | 46.5 (1.1-93.0) |
| 0 additional mutations, n (%) | 118 (63) | 4 (67) | 42 (67) | 16 (84) | 56 (55) |
| 1 additional mutation, n (%) | 38 (20) | 2 (33) | 11 (18) | 1 (5) | 24 (24) |
| ≥2 additional mutations, n (%) | 32 (17) | 0 (0) | 8 (13) | 2 (11) | 22 (22) |
| Therapy | |||||
| Intensive induction, n (%) | 40 (21) | 0 (0) | 1 (2) | 1 (5) | 38 (37) |
| HMA, n (%) | 106 (56) | 0 (0) | 39 (64) | 15 (79) | 52 (51) |
| Venetoclax, n (%) | 70 (37) | 0 (0) | 12 (20) | 7 (37) | 51 (50) |
| Stem cell transplant, n (%) | 23 (12) | 0 (0) | 11 (18) | 2 (11) | 10 (10) |
| Characteristic . | Total cohort (N = 188) . | CCUS (n = 6) . | MDS and MDS/AML (n = 80) . | AML (n = 102) . | |
|---|---|---|---|---|---|
| 0% to <10% blasts (n = 61) . | 10% to <20% blasts (n = 19) . | ≥20% blasts . | |||
| Age at dx (y), median (range) | 68.5 (28.0-88.0) | 69.5 (56.5-79.1) | 68.5 (38.0-84.0) | 71.1 (38.5-81.0) | 68.3 (28.0-88.0) |
| Sex, male, n (%) | 98 (52) | 3 (50) | 27 (44) | 13 (68) | 55 (54) |
| CBC at dx, median (range) | |||||
| ANC, ×103/μL | 0.8 (0-16.1) | 2.7 (0.5-4.6) | 1.4 (0.1-11.5) | 1.2 (0.3-2.5) | 0.6 (0.0-16.1) |
| Hb, g/dL | 8.4 (5.5-14.1) | 10.6 (7.3-13.2) | 8.8 (5.6-13.8) | 8.4 (6.6-12.3) | 8.3 (5.5-14.1) |
| Plt, ×103/μL | 48 (7-347) | 123 (81-232) | 62 (7-347) | 51 (8-114) | 36 (7-228) |
| BM blast %, median (range) | 23 (0-100) | 2 (0.5-2.5) | 3 (0-9.5) | 15 (10-17.5) | 35 (20.8-100) |
| Karyotype | |||||
| Complex, n (%) | 161 (86) | 0 (0) | 47 (77) | 19 (100) | 95 (93) |
| Monosomal, n (%) | 154 (82) | 0 (0) | 46 (75) | 17 (90) | 91 (89) |
| Del 17/17p, n (%) | 56 (30) | 0 (0) | 12 (20) | 4 (21) | 40 (40) |
| Mutations by NGS | |||||
| 1 TP53 mutation, n (%) | 145 (77) | 6 (100) | 43 (70) | 15 (79) | 80 (78) |
| ≥2 TP53 mutations, n (%) | 43 (23) | 0 (0) | 18 (30) | 4 (21) | 21 (21) |
| Highest TP53 VAF, median (range) | 41 (1.1-97) | 8.9 (4.5-14.0) | 35 (4-97) | 41 (4-89) | 46.5 (1.1-93.0) |
| 0 additional mutations, n (%) | 118 (63) | 4 (67) | 42 (67) | 16 (84) | 56 (55) |
| 1 additional mutation, n (%) | 38 (20) | 2 (33) | 11 (18) | 1 (5) | 24 (24) |
| ≥2 additional mutations, n (%) | 32 (17) | 0 (0) | 8 (13) | 2 (11) | 22 (22) |
| Therapy | |||||
| Intensive induction, n (%) | 40 (21) | 0 (0) | 1 (2) | 1 (5) | 38 (37) |
| HMA, n (%) | 106 (56) | 0 (0) | 39 (64) | 15 (79) | 52 (51) |
| Venetoclax, n (%) | 70 (37) | 0 (0) | 12 (20) | 7 (37) | 51 (50) |
| Stem cell transplant, n (%) | 23 (12) | 0 (0) | 11 (18) | 2 (11) | 10 (10) |
ANC, absolute neutrophil count; CBC, complete blood count; dx, diagnosis; Hb, hemoglobin; HMA, hypomethylating agent; NGS, next-generation sequencing; Plt, platelets.